Mycobacterial infectious disease

Summary

Mycobacterial infectious disease (MONDO:0020590) is a disease (an umbrella term covering 7 Mondo subtypes) and 19 clinical trials. Top therapeutic interventions include bedaquiline, clofazimine, and btz-043. A subtype of bacterial infectious disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Umbrella term: 7 Mondo subtypes
• Clinical trials: 19

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	mycobacterial infectious disease
Mondo ID	MONDO:0020590
MeSH	D009164
NCIT	C26831
SNOMED CT	88415009
UMLS	C0026918
MedGen	6479
Is cancer (heuristic)	no

Also known as: mycobacterial infection · mycobacteriosis · mycobacterium infection

Disease family

This is a subtype of bacterial infectious disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › bacterial infectious disease › mycobacterial infectious disease

Related subtypes (51): primary bacterial infectious disease, commensal bacterial infectious disease, opportunistic bacterial infectious disease, chorioamnionitis, Clostridium difficile colitis, bacterial gastritis, bacterial arthritis, bacterial pneumonia, Whipple disease, Aeromonas hydrophila infectious disease, Pectobacterium carotovorum infection, Pseudomonas infection, septic peritonitis, bacterial infectious disease with sepsis, empyema, bacterial urinary tract infection, bacterial sexually transmitted disease, meningococcal infection, pasteurellosis, peritonsillar abscess, pneumonic pasteurellosis, tracheitis, Actinobacillus infectious disease, bacterial conjunctivitis, bacterial endocarditis, bacterial meningitis, Bifidobacteriales infectious disease, haemophilus infectious disease, Proteus infectious disease, pulpitis, rat-bite fever, Rickettsiosis, vibrio infectious disease, Yersinia infectious disease, bacterial myositis, noma, idiopathic severe pneumococcemia, necrotizing soft tissue infection, escherichia coli infection, gram-negative bacterial infections, gram-positive bacterial infections, spirochaetales infections, skin disease caused by bacterial infection, staphylococcal infection, anaerobic bacteria infectious disease, Klebsiella infectious disease, fournier gangrene, botryomycosis, bacterial hemorrhagic fever, Mycoplasmoides infection, Enterococcus infectious disease

Subtypes (7): Buruli ulcer disease, leprosy, Mycobacterium avium complex disease, Mycobacterium xenopi infection, tuberculosis, pulmonary non-tuberculous mycobacterial infection, aquarium granuloma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

0 approved, 4 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Amikacin	Phase 3 (in late-stage trials)
Azithromycin	Phase 3 (in late-stage trials)
Ethambutol	Phase 3 (in late-stage trials)
Rifabutin	Phase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): INTERFERON GAMMA-1B, Molgramostim.

Clinical trials & evidence

Clinical trials

Clinical trials: 19.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	14
PHASE1	3
PHASE3	1
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03896685	PHASE3	COMPLETED	Evaluating Newly Approved Drugs in Combination Regimens for Multidrug-Resistant TB With Fluoroquinolone Resistance (endTB-Q)
NCT00004276	PHASE2	COMPLETED	Phase II Placebo Controlled Study of Thalidomide in Patients With Mycobacterial and HIV Infections
NCT00001515	PHASE1	COMPLETED	Diagnostic Effectiveness of Virtual Bronchoscopy
NCT03590600	PHASE1	COMPLETED	A Single Ascending Dose Study of BTZ043
NCT04874948	PHASE1	COMPLETED	Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB Treatment
NCT00018044	Not specified	RECRUITING	Study of Mycobacterial Infections
NCT01212003	Not specified	RECRUITING	Training Protocol on the Natural History of Tuberculosis
NCT05336851	Not specified	RECRUITING	Emergency PWAS in Respiratory Infectious Disease
NCT05610098	Not specified	RECRUITING	Gene Expression Profiles in Spinal Tuberculosis.
NCT05824988	Not specified	RECRUITING	Drug Exposure and Minimum Inhibitory Concentration in the Treatment of MAC Lung Disease
NCT06155747	Not specified	RECRUITING	Transmission and Acquisition of Nontuberculous Mycobacteria Outbreak Investigation (TrANsMIt)
NCT06262282	Not specified	ENROLLING_BY_INVITATION	Mycobacteriophage Treatment of Non-tuberculosis Mycobacteria
NCT06266442	Not specified	RECRUITING	M. Avium WGS During Mav-PD Treatment
NCT06764576	Not specified	RECRUITING	Patients With Tuberculosis, Mycobacteriosis or Latent Tuberculosis
NCT00999076	Not specified	TERMINATED	Rapid Identification of Mycobacteria in Acid-fast Bacilli Smear-positive Respiratory Specimens
NCT01547884	Not specified	COMPLETED	Effect of Filarial Infection on Immune Responses in Latent Tuberculosis
NCT01628744	Not specified	UNKNOWN	Autoantibodies Against Specific Cytokines in Adults With Severe Mycobacterial Infection
NCT02913365	Not specified	UNKNOWN	Etiologies, Investigations and Outcomes of Patients Presenting With Hemoptysis
NCT04783727	Not specified	TERMINATED	PredictEndTB Signature for Individualizing Treatment in Multidrug-Resistant Tuberculosis

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
BEDAQUILINE	4	1
CLOFAZIMINE	4	1
BTZ-043	2	1
CHEMBL426123	0	1